Payment overview · 2025
General Payments
$2,811.70
118 reported records · 26 companies
Healthcare provider profile · identity verified
Alejandro N Lopez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SPARTANBURG, SC · NPI 1639126733
Verified facts
What the public records show
CMS Open Payments records show Alejandro N Lopez, M.D. received $2,811.70 in general payments during 2025 across 118 reported records.
Medtronic, Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Nexletol.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Brilinta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexletol by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$587.96 | 20.9% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $371.77 | 13.2% | 28 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $236.91 | 8.4% | 11 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $235.92 | 8.4% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $210.09 | 7.5% | 9 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $176.84 | 6.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $176.72 | 6.3% | 10 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $110.39 | 3.9% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $91.23 | 3.2% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $80.60 | 2.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.11 | 2.0% | 4 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $52.93 | 1.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $52.20 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.49 | 1.6% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.13 | 1.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.30 | 1.3% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $33.95 | 1.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.81 | 1.2% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $32.92 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.61 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.93 | 0.9% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $23.72 | 0.8% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $20.17 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.06 | 0.6% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $15.30 | 0.5% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $13.64 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,501.68 | 116 |
| Travel and Lodging | $310.02 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $523.06 | 5 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $235.92 | 6 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $218.72 | 14 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $176.84 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $176.72 | 10 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $110.39 | 3 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $93.55 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $80.60 | 10 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $76.49 | 11 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $60.90 | 2 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $52.93 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $52.20 | 1 | 2025 |
Source payment records
|
|||||
| Wolverine Coronary Cutting Balloon Normalized: wolverine coronary cutting balloon |
Device | Boston Scientific Corporation | $46.47 | 2 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.62 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $12.87 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $12.62 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $12.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 439 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 38 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
121 | 37 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
439 | 109 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
439 | 109 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 574 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 164 |
| Eliquis | Apixaban | 439 | 109 |
| Carvedilol | Carvedilol | 400 | 124 |
| Metoprolol Tartrate | Metoprolol Tartrate | 396 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 82 |
| Losartan Potassium | Losartan Potassium | 252 | 86 |
| Lisinopril | Lisinopril | 157 | 54 |
| Nitroglycerin | Nitroglycerin | 141 | 81 |
| Brilinta | Ticagrelor | 121 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 103 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 40 |
| Xarelto | Rivaroxaban | 95 | 21 |
| Furosemide | Furosemide | 91 | 41 |
| Ezetimibe | Ezetimibe | 88 | 25 |
| Ranolazine Er | Ranolazine | 85 | 18 |
| Warfarin Sodium | Warfarin Sodium | 82 | 26 |
| Spironolactone | Spironolactone | 70 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 17 |
| Flecainide Acetate | Flecainide Acetate | 59 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 21 |
| Potassium Chloride | Potassium Chloride | 59 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 25 |
| Prasugrel Hcl | Prasugrel Hcl | 57 | 11 |
| Repatha Sureclick | Evolocumab | 43 | 13 |
| Entresto | Sacubitril/Valsartan | 38 | 11 |
| Bumetanide | Bumetanide | 34 | 11 |
| Simvastatin | Simvastatin | 31 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Sotalol | Sotalol Hcl | 22 | 12 |
| Valsartan | Valsartan | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,811.70 · 118 records | Medtronic, Inc. | ABRE, ABRYSVO, ANGIOVAC, AVVIGO Guidance System, Ambulatory Monitoring & Diagnostics Undivided, Attruby, Barostim Neo System, BodyGuardian, CAMZYOS, CARDIVA VASCADE 6/7F VCS, CDS - MCT/CEM Monitoring, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Coronary Other, ELIQUIS, ENTRESTO, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ESPRIT, Eagle Eye, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Flexitouch Plus, HAWKONE, IN.PACT ADMIRAL, KENGREAL, LEQVIO, LOKELMA, LifeVest, NEXLETOL, Nimbl, ONPATTRO, OptiCross, PREVNAR 20, PROTEGE RX, Paradise Ultrasound Renal Denervation System, REPATHA, SAPIEN 3 Ultra RESILIA, SYNERGY, Serrantor, VENACORE THROMBECTOMY CATHETER, VERQUVO, VYNDAQEL, WATCHMAN FLX, Wolverine Coronary Cutting Balloon | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error